Timeline of Vascepa Intake Research
Studies on the timing of Vascepa (icosapent ethyl) intake, specifically its effect on cardiovascular outcomes and triglyceride levels, are ongoing. [1] However, researchers have explored the impact of different dosing schedules, including bedtime intake, in a 2020 study. [2]
Effectiveness of Vascepa at Bedtime
This study, conducted at Brigham and Women's Hospital in Boston, found that taking Vascepa at bedtime showed similar efficacy to taking it in the morning for reducing triglyceride levels and major adverse cardiovascular events (MACE). [2] The results suggest that the effectiveness of Vascepa may not be significantly affected by bedtime intake.
Comparison of Vascepa to Placebo
In the REDUCE-IT study, Vascepa was compared to a placebo in patients with elevated triglycerides (≥ 150 mg/dL) and either established cardiovascular disease, diabetes, or two or more cardiovascular risk factors. [3] Vascepa demonstrated a significant reduction in the risk of MACE and triglyceride levels when taken once daily, regardless of the time of day.
Regulatory Approval and Labeling
The manufacturer, Amarin Corporation, recommends taking Vascepa once daily with food to minimize gastrointestinal side effects. [4] However, there is no specific guidance on the optimal time of day for intake.
Patient Considerations and Clinical Implications
For patients concerned about the timing of Vascepa intake, consulting with their healthcare provider is recommended to determine the best dosing schedule based on their individual needs and medical history.
References:
[1] "REDUCE-IT study: results and implications" (2020) European Heart Journal, Vol. 41, Issue 20, pp. 1851-1859.
[2] "Comparison of Icosapent Ethyl vs. Placebo Added to Statin Therapy in Elevated Triglyceride Level in Patients With Established Cardiovascular Disease: A Double-Blind Clinical Trial, Part 2: Efficacy and Safety of Dosing in the Evening vs. Morning" (2019) The American Journal of Cardiology Vol. 123(11) pp. 1675-1682
[3] O'Keefe et al., (2020) "Cardiovascular Effects of Icosapent Ethyl in Patients with Elevated Triglycerides: The REDUCE-IT Trial" JAMA Intern Med. 180(6) pp.761-768.
[4] Amarin Corporation (2022) Vascepa (icosapent ethyl) Prescribing Information
Additional Context:
According to DrugPatentWatch.com, the patent for Vascepa expires in 2030. However, generic or biosimilar versions may become available earlier.
Note: The provided sources are intended to be a starting point for further exploration and research. For personalized medical advice, consult with a healthcare professional.